Wuxi Biologics and Harbin Gloria out-licensed cancer drug to Arcus Biosciences

| By | Cancer Drugs, Drug Development, R&D

WuXi Biologics, a global leading open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and its Chinese partner Harbin Gloria Pharmaceuticals Co Ltd, today announced that an exclusive license to the anti-PD-1 antibody GLS-010 has been granted to Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies.

Gloria contracted WuXi Biologics to discover and develop GLS-010, a novel anti-PD-1 antibody, using Ligand’s transgenic rat platform OmniRat®. GLS-010 is currently being evaluated in cancer patients in phase I clinical studies in . Arcus has licensed the exclusive development and commercialization rights of GLS-010 in North America, Europe, Japan and certain other territories.

Arcus plans on developing GLS-010 as a combination product with the other product candidates in its portfolio.

“We are pleased that our integrated platform has enabled companies such as Gloria to enter into biologics with an exciting program. We are also excited to enter into this agreement to expedite biologics development to treat patients globally,” commented Dr. Chris Chen, CEO and executive director of WuXi Biologics. “This new partnership continues to reinforce the value of our integrated service platform, the global quality WuXi Biologics commits to, and the success of our ‘follow-the-molecule’ strategy”.

“We are thrilled to gain access to GLS-010 in our territories,” commented Dr. Tim Sullivan, Vice President of Business Development at Arcus. “This molecule will enable us to fully exploit the potential of our other immuno-oncology agents for the benefit of patients. Working with WuXi Biologics also ensures high-quality clinical supply of our biologics, an essential operational component of our strategy to develop a series of novel and best-in-class combination therapies for the treatment of cancer.”

SOURCE: prnewswire.com
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.